Stamford, CT -- (SBWIRE) -- 01/04/2014 -- Jet Life Penny Stocks provides investors with the some of the most Awesome Penny Stock alerts on a regular basis. We will send you alerts through our Penny Stock Newsletter and offer you the tools to help you along the way with the goal of keeping you loyal to our service. Here are some trending Stocks in focus: DARA Biosciences Inc (NASDAQ:DARA), Frontline Ltd. (NYSE:FRO), AEterna Zentaris Inc. (USA)(NASDAQ:AEZS), Origin Agritech Ltd. (NASDAQ:SEED)
DARA Biosciences Inc (NASDAQ:DARA) opened its shares at the price of $0.60 for the day. Its closing price was $0.610 after gaining +3.39% for the day. The company traded with the total volume of 1.99 million shares, while its average trading volume remained 825,619.00 shares. The beta of DARA stands at1.50. DARA BioSciences, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of oncology treatment and supportive care pharmaceutical products in the United Sates.
For How Long DARA will Fight for Profitability? Read This Trend Analysis report
Frontline Ltd. (NYSE:FRO) percentage change surged +5.85% to close at $3.80 with the total traded volume of 1.96 million shares, and average volume of 1.73 million. The 52 week range of the stock remained $1.71 - $4.05, while its day lowest price was $3.68 and it hit its day highest price at $3.93. Frontline Ltd., through its subsidiaries, engages in the ownership and operation of oil tankers.
For How Long FRO’s Gloss will Attract Investors? Find out via this report
AEterna Zentaris Inc. (USA)(NASDAQ:AEZS) started its trading session with the price of $1.49 and closed at $1.46 by scoring +1.39%. AEZS’s stocks traded with total volume of 1.90 million shares, while the average trading volume remained 2.70 million shares. The beta of AEZS stands at 1.37. Day range of the stock was $1.41 -$1.50. Aeterna Zentaris Inc. (NASDAQ: AEZS) is a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company's pipeline encompasses compounds from drug discovery to regulatory approval. Its lead oncology program is an ongoing Phase 3 trial in endometrial cancer with zoptarelin doxorubicin (formerly AEZS-108). Its lead endocrinology product is macimorelin acetate (formerly AEZS-130) for which an NDA has been submitted to the FDA, seeking approval for the marketing and sales of macimorelin acetate as the first orally-administered product that induces growth hormone release to evaluate Adult Growth Hormone Deficiency (AGHD). Its pipeline also encompasses other earlier-stage programs in both oncology and endocrinology.
Will AEZS Continue To Move Higher? Find Out Here
Origin Agritech Ltd. (NASDAQ:SEED) ended its day with the gain of +44.80% and closed at the price of $1.84 after opening at $1.27. Stock traded during its last trading session with the total volume of 1.91 million shares, as compared to its average volume of 104,082.00 shares. Origin Agritech Limited, an agricultural biotechnology company, specializes in crop seed breeding and genetic improvement activities in the People’s Republic of China.
Why Should Investors Buy SEED After The Recent Gain? Just Go Here and Find Out
Jet Life Penny Stocks is always searching the market every day for massive penny stock runs before they happen so you don't have to. Our Penny Stock Newsletter also offers free Highly-Professional Grade stock charts and video charts from one of the most experienced and well-respected chartists in the penny stock industry.
Jet Life Penny Stocks is not a registered securities advisor. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides information on highlighted stocks via press releases, newsletters and company website, but this should not be construed as a recommendation to buy or sell. Please visit the company website for a more complete list of risks and disclosures.
Read full disclaimer at: http://www.jetlifepennystocks.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)